Immunovaccine Names Joseph Sullivan, Experienced Global Pharmaceutical and Vaccine Executive, as Senior Vice President, Business Development
“Joe is a seasoned corporate development leader in the pharmaceutical and vaccine industry,” said Frederic Ors, Immunovaccine’s Chief Executive Officer. “His experience, relationships, and reputation for strategic and operational excellence will be crucial as we move into a pivotal year for
Mr. Sullivan’s pharmaceutical career has focused on leading product teams and external collaborations, identifying novel vaccine targets and technologies for development, and operationalizing global launch and commercialization plans. Most recently, he served as the Executive Director, Partner Strategy and Implementation Lead, at
“The vaccine and immunotherapy space is very dynamic and continues to rapidly advance to address unmet medical needs. Immunovaccine’s product research and clinical development achievements thus far, including the DepoVax technology, may offer healthcare providers much-needed new options for their patients’ care,” said Mr. Sullivan. “I am excited to be part of this team and intend to leverage my broad experience with industry and major stakeholders to help accelerate the growth and realize the potential of this Company and its programs.”
Mr. Sullivan has an M.B.A. from
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals.
T: (312) 961-2502 E: firstname.lastname@example.org
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: email@example.com
O: (415) 513-1284
T: (415) 515-4572 E: firstname.lastname@example.org
i Gardasil® and Singulair® are registered trademarks of
Source: Immunovaccine Inc.